India should eliminate tax on drugs for cancer treatment and for chronic and rare diseases, the chairperson of major ...
The market may extend its upward journey, but sustainability is the key to watch, given the elevated volatility. Below are ...
Shaw, Chairperson of Biocon, has urged the government to remove tax on medicines used to treat cancer, chronic illnesses, and ...
According to reports, HSBC said that Biocon is well-placed for an operational turnaround, driven by key biosimilar launches ...
Brokerages have turned bullish over Biocon's growth prospects after the US FDA clearance of the drugmaker's Malaysia unit ...
With an increased confidence in the company’s prospects, HSBC raised its earnings estimates for Biocon, projecting ...
Biocon has experienced a significant earnings decline over the past two years, led by a lack of potential approvals for the U ...
HSBC expects an operational turnaround for Biocon, driven by major biosimilar launches and a rebound in generics sales. The ...
CCI fines Goldman Sachs for undisclosed investment in Biocon, highlighting need for compliance with competition laws in ...
The Competition Commission of India fined Goldman Sachs AIMPL Rs 40 lakh for not notifying it about a deal that included ...
Biocon’s share price climbed to an intraday high of Rs 377.50 per share in intraday trade on the Bombay Stock Exchange (BSE).
Biocon Ltd share price was up by 0.14% from the previous closing price of ₹393.15. Who are peers of Biocon Ltd? The peers of Biocon Ltd are Sun Pharmaceuticals Industries Ltd, Divis Laboratories ...